Your browser doesn't support javascript.
loading
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial.
Sarraju, Ashish; Li, JingWei; Cannon, Christopher P; Chang, Tara I; Agarwal, Rajiv; Bakris, George; Charytan, David M; de Zeeuw, Dick; Greene, Tom; Heerspink, Hiddo J L; Levin, Adeera; Neal, Bruce; Pollock, Carol; Wheeler, David C; Yavin, Yshai; Zhang, Hong; Zinman, Bernard; Perkovic, Vlado; Jardine, Meg; Mahaffey, Kenneth W.
Affiliation
  • Sarraju A; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
  • Li J; The George Institute for Global Health, UNSW Sydney, New South Wales, Australia.
  • Cannon CP; Cardiovascular Division, Brigham & Women's Hospital and Baim Institute for Clinical Research, Boston, MA.
  • Chang TI; Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
  • Agarwal R; Indiana University School of Medicine and VA Medical Center, Indianapolis, Indiana.
  • Bakris G; Department of Medicine, University of Chicago Medicine, Chicago, IL.
  • Charytan DM; Nephrology Division, NYU School of Medicine and NYU Langone Medical Center, New York, NY.
  • de Zeeuw D; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Greene T; Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, UT.
  • Heerspink HJL; The George Institute for Global Health, UNSW Sydney, New South Wales, Australia; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Levin A; Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Neal B; The George Institute for Global Health, UNSW Sydney, New South Wales, Australia; Imperial College London, London, UK.
  • Pollock C; Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Wheeler DC; The George Institute for Global Health, UNSW Sydney, New South Wales, Australia; Department of Renal Medicine, UCL Medical School, London, UK.
  • Yavin Y; Janssen Research & Development, LLC, Raritan, NJ.
  • Zhang H; Renal Division of Peking University First Hospital, Beijing, China.
  • Zinman B; Lunenfeld-Tanenbaum Research Institute, Mt Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Perkovic V; The George Institute for Global Health, UNSW Sydney, New South Wales, Australia; The Royal North Shore Hospital, Sydney, Australia.
  • Jardine M; The George Institute for Global Health, UNSW Sydney, New South Wales, Australia.
  • Mahaffey KW; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA. Electronic address: Kenneth.Mahaffey@stanford.edu.
Am Heart J ; 233: 141-148, 2021 03.
Article in En | MEDLINE | ID: mdl-33358942
We aimed to assess the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy according to prior history of heart failure in the Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) trial. We found that participants with a prior history of heart failure at baseline (15%) were more likely to be older, female, white, have a history of atherosclerotic cardiovascular disease, and use diuretics and beta blockers (all P < .001), and that, compared with placebo, canagliflozin safely reduced renal and cardiovascular events with consistent effects in patients with and without a prior history of heart failure (all efficacy P interaction >.150). These results support the efficacy and safety of canagliflozin in patients with type 2 diabetes and nephropathy regardless of prior history of heart failure.
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Renal Insufficiency, Chronic / Canagliflozin / Sodium-Glucose Transporter 2 Inhibitors / Heart Failure Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Am Heart J Year: 2021 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Renal Insufficiency, Chronic / Canagliflozin / Sodium-Glucose Transporter 2 Inhibitors / Heart Failure Type of study: Clinical_trials Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Am Heart J Year: 2021 Document type: Article Country of publication: United States